- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma, Multiple Myeloma
- Interventions
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG, Antibiotics, Anti-viral agents, Anti-fungal agent, Anti-emetics
- Biological · Diagnostic Test · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 5,290
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult ALL, Healthy
- Interventions
- Carbon Fiber Custom Dynamic Orthosis (CDO)
- Device
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Interventions
- carfilzomib, Cytokine Assessment, Pharmacodynamic Studies, Proteosome Inhibition Assessment, Pharmacogenomic Studies
- Drug · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- mycophenolate mofetil, tacrolimus
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
- Interventions
- MEDI-507, Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- busulfan, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hairy Cell Leukemia
- Interventions
- binimetinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia, Lymphoma, Bone Marrow Failure, Immunodeficiencies, Histiocytosis, Sickle Cell Disease, Beta Thalassemia, Inborn Errors of Metabolism
- Interventions
- Full Intensity with TBI, Full Intensity, Reduced Intensity, Reduced Intensity (Fanconi)
- Drug
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Gemtuzumab Ozogamicin, Venetoclax
- Drug
- Lead sponsor
- John Quigley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- San Francisco, California • Winston-Salem, North Carolina
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
- Interventions
- BMS-214662, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Leukemia, Lymphoma
- Interventions
- dolastatin 10
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 1 more
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Interventions
- Dasatinib, Decitabine and Cedazuridine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels
- Interventions
- nilotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Las Vegas, Nevada • Amarillo, Texas • Dallas, Texas
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- biologic sample preservation procedure
- Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 1,294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 292
- States / cities
- Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more
- Conditions
- Leukemia, B-cell Leukemia, Chronic Leukemia, Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Alemtuzumab, Fludarabine, Cytoxan
- Drug
- Lead sponsor
- Steven E. Coutre
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- FluCAM [Fludara + Campath], fludarabine phosphate
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Fort Myers, Florida
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,043 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Troxatyl™ (troxacitabine)
- Drug
- Lead sponsor
- SGX Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 20
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 16 more
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- cyproheptadine hydrochloride, megestrol acetate
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 40
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 4 more
- Conditions
- Hodgkin's Disease, Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Interventions
- Cognitive Behavioral Therapy: Questionnaires, Usual Care: Questionnaires
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Interventions
- Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Mitoxantrone, Sorafenib
- Drug · Biological · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myelogenous Leukemia
- Interventions
- Imatinib, Nilotinib (AMN107)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Anaheim, California • Baldwin Park, California + 32 more